Every 8-K that ZEO SCIENTIFIX INC (ZEOX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZEOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZEOX filings page.
Zeo ScientifiX, Inc. (ZEOX) has changed its fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. This change was approved by the Board of Directors and became effective on September 10, 2026.
The transition period created by this change is the eight-month period from November 1, 2025 through June 30, 2026. Zeo ScientifiX plans to file a transition report on Form 10-KT covering this transition period, within the time period required by applicable Securities and Exchange Commission rules.
Zeo ScientifiX, Inc. (ZEOX) reported that it plans to expand its commercial and provider-support presence into Georgia and Tennessee, aligning with newly enacted state laws that establish frameworks for certain stem cell and regenerative medicine therapies. The company intends to support healthcare professionals with regenerative biologics, scientific resources, physician education, and operational guidance tailored to each state’s regulatory requirements.
The expansion builds on Zeo ScientifiX’s existing activities in Florida under that state’s 2025 law and is positioned as part of a broader national growth strategy. The company highlights that the new state laws do not constitute U.S. Food and Drug Administration approval and that providers remain responsible for compliance with all applicable federal and state requirements, licensing rules, and standards of care.
Zeo ScientifiX, Inc. (ZEOX) reported that it has announced the faculty and guest speaker lineup for its inaugural ZEO Xperience, a three-day immersive regenerative medicine educational event for healthcare professionals. The program will be held October 23–25, 2026 at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida, with multidisciplinary experts spanning clinical specialties, regulatory law, regenerative science, and healthcare business. The event extends the company’s physician-education platform, which also includes Master Classes, webinars, scientific programming, and clinical collaborations, and is intended to foster direct interaction and knowledge-sharing among attendees and faculty.
ZEO ScientifiX, Inc. announced the launch of ZEO Xperience, its inaugural three-day immersive educational experience for healthcare professionals focused on regenerative medicine and biologics. The event is scheduled for October 23–25, 2026 at Pier Sixty-Six Resort in Fort Lauderdale, Florida.
ZEO Xperience is structured around three themed days: Science & Innovation, Clinical Training & Practice Growth, and a Biohacking Experience. Programming combines evidence-based scientific education, hands-on clinical training, business development strategies, and wellness technologies, aligning with the company’s mission to advance physician education and responsible adoption of regenerative biologic therapies.
ZEO ScientifiX, Inc. describes new efforts to strengthen its role within South Florida’s healthcare innovation ecosystem. On July 21, 2026, the company highlighted regenerative biologic research and development, physician education, and scientific collaboration as core focus areas, operating from Nova Southeastern University’s Center for Collaborative Research in Davie, Florida.
The company is expanding physician Master Classes, webinars, scientific programming, professional collaborations, and its Medical Advisory Board to connect emerging regenerative medicine science with clinical practice. ZEO ScientifiX presents these initiatives as supporting meaningful scientific exchange and the responsible advancement of regenerative medicine from a South Florida base.
ZEO ScientifiX, Inc. reported very strong growth for the quarter and six months ended April 30, 2026, highlighted in a press release tied to its latest Form 10-Q. Quarterly revenue reached $2.58 million, up 124.6% from $1.15 million a year earlier, driven mainly by higher sales of allogenic biologic products.
For the six-month period, revenue was $4.03 million, an increase of 79.9% from $2.24 million in the prior year period. The company maintained gross margins of about 80% in both 2026 and 2025 six-month periods while reducing its net loss to roughly $1.0 million from about $2.6 million a year earlier. Management attributes this to accelerating commercial momentum, growing physician adoption, and rising demand for its regenerative biologics portfolio.
ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational initiative for healthcare professionals. The company will host a live virtual webinar titled “One Year Later, Three States Stronger: The Southeast Regen Revolution” on July 22, 2026, at 6:45 p.m. Eastern Time.
The program will review Florida’s first year under its pioneering stem cell law and discuss similar laws recently adopted in Tennessee and Georgia. Led by General Manager Sean Vega-Stanton, M.D., the expert panel will cover scientific, medical, and regulatory perspectives in regenerative medicine.
ZEO ScientifiX, Inc. filed a report describing a humanitarian initiative supported by the company. Medical Advisory Board member Dr. Constantino Mendieta joined a 10-day pediatric burn reconstruction mission in Cusco, Peru, where he used products that had been donated to him by ZEO ScientifiX.
During the mission, approximately 80 children were evaluated and nearly 40 reconstructive surgeries were performed over six days at the Regional Hospital of Cusco. ZEO frames this product donation as part of a broader commitment to physician-led care, regenerative medicine education, and expanding access to advanced therapeutic options for patients in need.
Zeo ScientifiX, Inc. reported new stock option awards under its 2021 Incentive Stock Plan. On June 10, 2026, the company granted options for 625,000 shares of common stock each to Greyt Ventures LLC, CEO/CFO and director Ian Bothwell, and Chief Medical Officer and director George Shapiro. These options are fully vested, exercisable on a cashless basis for ten years, with an exercise price of $1.67 per share.
The company also granted 625,000 additional “Incentive Options” to each of Greyt Ventures LLC, Bothwell, and Shapiro that vest upon achievement of specified performance milestones and are exercisable on a cashless basis for ten years at $1.67 per share. These Incentive Options are described as antidilutive for any future transaction that issues 10% or more of common stock on a fully diluted basis. In addition, Zeo ScientifiX awarded options for 80,000 shares to non-executive director Chuck Bretz, fully vested at grant, exercisable for five years at $1.67 per share.
ZEO ScientifiX, Inc. expanded its Medical Advisory Board by adding nine physicians and scientific innovators across disciplines such as orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies. The board is positioned as a core scientific body focused on research, clinical protocols, and high clinical standards rather than marketing endorsements.
The advisors will guide scientific development, regenerative biologics, and physician education, including programs like the Physician-Led Patient Masterclass and initiatives connected to the $101 million XPRIZE Healthspan longevity prize competition, where the company is a semi-finalist. ZEO ScientifiX describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics and physician education.
ZEO ScientifiX, Inc. filed a current report describing the launch of its new Physician-Led Patient Masterclass program in regenerative medicine. The program is designed to help doctors educate current and potential patients on the science, appropriate use cases, and safety considerations of regenerative therapies.
ZEO notes it has trained more than 600 physicians across the Southeast in the past year on clinical applications of regenerative therapies, including stem cell use for pain management, wound care, and orthopedics under Florida law. The new Masterclass formalizes a physician-hosted, locally tailored patient education model that the company now plans to roll out across its Florida physician network.
ZEO ScientifiX, Inc. reported that unaudited sales for April 2026 surpassed $1 million in a single month for the first time in the Company’s history. Management describes this as a commercial inflection point for its regenerative medicine products business serving physician-run clinics across the United States.
The Company attributes this milestone mainly to a newly implemented dedicated internal sales force and a “physician-first” commercial strategy. ZEO plans to hire additional full-time sales professionals to accelerate physician onboarding and deepen penetration in existing clinic networks, alongside expanding its physician education and masterclass programs.
Executives emphasize that breaking through the $1 million-per-month level acts as proof of concept for the model and that the existing sales and educational infrastructure is designed to support further growth, while reminding readers that these expectations are forward-looking and subject to risks and uncertainties.
ZEO ScientifiX, Inc. filed a report describing a business milestone rather than financial results. The company announced that its monthly Masterclass series in regenerative biologics has now trained over 500 clinicians, with each one-day session typically hosting more than 70 attendees at Nova Southeastern University in Florida.
The curriculum focuses on Florida regulatory requirements, evidence-based science, and operational frameworks for responsibly integrating regenerative biologics such as stem cells and extracellular vesicles into medical practice. The next Masterclass is scheduled for April 24 and is limited to clinicians and practice owners.
ZEO ScientifiX, Inc. reported that it has entered into a memorandum of understanding with Regen Therapy for an exclusive scientific and biologics strategic collaboration. ZEO is positioned as the core supplier of advanced biologic therapeutics for Regen’s next-generation regenerative offerings across a network of more than 3,000 clinics and 24,000 practitioners in the U.S. The collaboration is paired with Regen Therapy’s partnership with Stealth Health and integration of the Metabolic Code precision health platform to create a vertically integrated ecosystem for telemedicine-driven longevity and regenerative care.
ZEO ScientifiX, Inc. reported that it has been selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition. This is a $101 million global contest aimed at therapeutics that restore muscle, cognitive, and immune function by at least 10 years in older adults.
The company is now preparing its Finals Application and plans to move its regenerative biologics platform into controlled clinical evaluation during the Semi-Finals. ZEO focuses on extracellular vesicle (exosome) therapeutics and advanced delivery systems targeting biological mechanisms of aging and inflammation, operating from laboratories at Nova Southeastern University.
ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational partnership with the American Academy of Anti-Aging Medicine (A4M) for Longevity SpringFest 2026. ZEO will serve as A4M’s official regenerative medicine education partner and lead a full-day Masterclass on April 9, 2026, in West Palm Beach, Florida.
The collaboration provides ZEO direct access to A4M’s network of 26,000 physicians and health care practitioners across more than 120 countries, positioning the company within the broader $29.9 billion longevity therapy market. ZEO describes itself as a clinical-stage biopharmaceutical company focused on regenerative biologics, operating from Nova Southeastern University’s $100 Million Center of Collaborative Research.
Zeo ScientifiX, Inc. reported that, effective March 23, 2026, it terminated the employment of Dr. John D. Kisiday, Ph.D. as its Chief Science Officer. This change removes a key scientific executive from the leadership team, and the company has not described any replacement or transition details in this excerpt.
Zeo ScientifiX, Inc. appointed Dr. John D. Kisiday as Chief Science Officer effective January 23, 2026. He brings nearly 30 years of experience in tissue engineering and regenerative medicine, including work with cell-based, biomaterial and drug-based orthopedic therapies and extensive academic research leadership.
Under an employment agreement effective the same date, Dr. Kisiday receives a $175,000 base salary and a 50,000-share stock grant under the 2021 Incentive Plan, vesting 20,000 shares after one year and 30,000 shares after two years, contingent on continued employment. His role is at-will and includes a tenure-based severance formula for termination without cause or for good reason, plus customary confidentiality, non-compete and non-solicitation covenants.
Zeo ScientifiX, Inc. awarded equity incentives to two senior executives. On January 14, 2026, the company granted 175,000 restricted shares of common stock under its 2021 Incentive Stock Plan to each of Ian Bothwell, who serves as Chief Executive Officer, Chief Financial Officer and director, and Dr. George Shapiro, the Chief Medical Officer and a director. These restricted shares are designed to vest over time, with 50% vesting on the eighth-month anniversary of the award date and the remaining 50% vesting on the one-year anniversary. This structure encourages ongoing service and aligns the executives’ interests with the company’s long-term performance.
Zeo ScientifiX, Inc. reported that it has entered into a comprehensive strategic partnership with Cytora Therapeutics Ltd. and Made Scientific, Inc. The collaboration focuses on advancing and commercializing Cytora’s novel allogeneic, off-the-shelf human oral mucosal stem cell therapy in the United States.
Cytora is described as a clinical-stage biotechnology company based in Israel, while Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization. The joint press release outlining additional details of the partnership is attached as Exhibit 99.1.
Zeo ScientifiX, Inc. announced a leadership change, making Ian T. Bothwell the company’s full-time Chief Executive Officer effective December 24, 2025. He had been serving as Interim Chief Executive Officer while also holding the role of Chief Financial Officer, and will continue in the dual position of Chief Executive Officer and Chief Financial Officer. This move formalizes the company’s executive leadership structure by confirming Bothwell as permanent CEO.
Zeo ScientifiX, Inc. reported that, effective November 30, 2025, it terminated the employment of Ron Borsheim as its Chief Sales Officer – Aesthetics. The company identifies itself as a Nevada corporation with principal offices in Davie, Florida, and it currently has no securities listed on a national securities exchange. The report is signed by Interim Chief Executive Officer and Chief Financial Officer Ian T. Bothwell, indicating executive-level oversight of this leadership change.
Zeo ScientifiX, Inc. filed an 8-K reporting that on October 23, 2025 it issued a press release stating the company is prepared to capitalize on the potentially rapid expansion of Florida’s regenerative medicine market following enactment of the new state stem cell law, SB 1768, effective July 1, 2025.
The press release is furnished as Exhibit 99.1 and incorporated by reference.